DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 203791
» See Plans and Pricing
The generic ingredient in SITAVIG is acyclovir. There are fifty-six drug master file entries for this compound. Additional details are available on the acyclovir profile page.
Summary for 203791
Tradename: | SITAVIG |
Applicant: | Epi Hlth |
Ingredient: | acyclovir |
Patents: | 3 |
Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 203791
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;BUCCAL | Strength | 50MG | ||||
Approval Date: | Apr 12, 2013 | TE: | RLD: | Yes | |||||
Patent: | Start Trial | Patent Expiration: | Jun 16, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | Start Trial | Patent Expiration: | Jun 3, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | Start Trial | Patent Expiration: | Mar 23, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription